Type: Synthetic peptide Amino Acid Length: Modified sequence derived from GLP1, GIP, and glucagon analogs Molecular Weight: Approximately ~50006000 Da (varies slightly by formulation and modifications) Structure: Linear peptide with chemical modifications to enhance stability, receptor specificity, and half-life Receptor Targets: GLP1R, GIPR, and GCGR Multi-Receptor Activation: Engages three hormone receptors simultaneously for synergistic metabolic effects Appetite Regulation: Activates GLP1 and GIP pathways in the CNS and pancreas to reduce food intake Energy Metabolism: Stimulates GCGR-mediated energy expenditure and fat oxidation Insulin and Glucose Control: Enhances insulin secretion and glucose homeostasis through incretin pathways Stability: Chemically modified to resist enzymatic degradation and prolong in vivo activity Weight Management: Reduces body weight via appetite suppression and increased energy expenditure Glycemic Control: Improves fasting glucose, insulin sensitivity, and HbA1c levels Metabolic Health: Potentially improves lipid metabolism, cardiovascular markers, and overall metabolic profile Water-Soluble: Suitable for in vitro and preclinical research Modified Linear Peptide: Includes amino acid substitutions and chemical modifications for enhanced receptor affinity and pharmacokinetics Half-Life: Optimized for once-weekly dosing in clinical trials Retatrutide is a synthetic, multi-receptor peptide with biochemical properties tailored for simultaneous GLP1, GIP, and glucagon receptor activation
Adjunctive treatments : Phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) may be prescribed to help manage erectile dysfunction
Understanding the pharmacological considerations of these transitions helps ensure smooth therapeutic continuity
Competing Interest The authors declare no competing interests
